论文部分内容阅读
目的：研究阿昔洛韦（ＡＣＶ） 复乳的口服生物利用度和肝靶向性。方法：采用高效液相色谱法测定大鼠口服ＡＣＶ 复乳和普通片剂后的血药浓度和肝组织分布，对试验数据进行药动学分析。药物浓度对时间数据作房室模型和统计矩解析，并求出相应的药动学参数。结果：大鼠口服ＡＣＶ 复乳对片剂的相对生物利用度为１４９－８ ％ ，达峰时间和血浓维持时间明显延迟。血浓经时过程符合二室开放线性药动学模型。血浓峰值附近的肝组织药物分布是片剂的１－６２ 倍（ Ｐ＜ ０－１） ，谷值附近是片剂的５－１６ 倍（ Ｐ＜ ０－０５） 。结论：大鼠口服ＡＣＶ 复乳可提高生物利用度，并有一定的肝靶向性
OBJECTIVE: To study the oral bioavailability and liver targeting of acyclovir (ACV) double emulsion. Methods: The plasma concentration and distribution of liver tissue were determined by high performance liquid chromatography (HPLC) after oral administration of ACV double emulsion and common tablets. The pharmacokinetics of the test data were analyzed. Drug concentration on the time data for atrioventricular model and statistical moment analysis, and find the corresponding pharmacokinetic parameters. Results: The relative bioavailability of rat oral ACV double emulsion was 149-8%, the peak time and blood concentration maintenance time was significantly delayed. The process of blood concentration in line with the two-compartment open linear pharmacokinetic model. Liver tissue drug distribution near peak blood concentrations was 1-62-fold (P <0-1) for tablets and 5-16-fold for tablets near the bottom (P <0-05). Conclusion: Rat oral administration of ACV can improve the bioavailability and have certain liver targeting